menu
    • menu
    [{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Aleor Dermaceuticals \/ Alembic Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Aleor Dermaceuticals \/ Alembic Pharmaceuticals Limited"},{"orgOrder":0,"company":"Lindenhofgruppe AG","sponsor":"Clinical Trials Unit Bern | Lindenhofstiftung | Labormedizinisches Zentrum Dr. Risch","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Lindenhofgruppe AG","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindenhofgruppe AG \/ Clinical Trials Unit Bern | Lindenhofstiftung | Labormedizinisches Zentrum Dr. Risch","highestDevelopmentStatusID":"1","companyTruncated":"Lindenhofgruppe AG \/ Clinical Trials Unit Bern | Lindenhofstiftung | Labormedizinisches Zentrum Dr. Risch"},{"orgOrder":0,"company":"Reig Jofre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Reig Jofre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Reig Jofre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reig Jofre \/ Undisclosed"},{"orgOrder":0,"company":"Destiny Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Destiny Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Destiny Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Destiny Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Health Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Horizon Health Network","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Horizon Health Network \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Horizon Health Network \/ Undisclosed"},{"orgOrder":0,"company":"Harvard Pilgrim Health Care","sponsor":"Hospital Corporation of America | University of California, Irvine | University of Massachusetts, Amherst | Rush University | Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Harvard Pilgrim Health Care","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Pilgrim Health Care \/ Hospital Corporation of America | University of California, Irvine | University of Massachusetts, Amherst | Rush University | Centers for Disease Control and Prevention","highestDevelopmentStatusID":"11","companyTruncated":"Harvard Pilgrim Health Care \/ Hospital Corporation of America | University of California, Irvine | University of Massachusetts, Amherst | Rush University | Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"Duke University","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Duke University \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Duke University \/ Bristol Myers Squibb"}]

    Find Clinical Drug Pipeline Developments & Deals for Mupirocin

    Menu

    Mupirocin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Duke University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Duke University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bacterial Decolonization Within Dyads

                            Details : Mupirocin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            August 07, 2024

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aleor Dermaceuticals

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Aleor Dermaceuticals

                            India arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Alembic Pharmaceuticals Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alembic Pharmaceuticals Announces Its Joint Venture Aleor Dermaceuticals Receives USFDA Final Approval for Mup...

                            Details : Mupirocin cream USP, 2% is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S. aureus and S. pyogenes.

                            Product Name : Mupirocin

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            November 17, 2021

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Alembic Pharmaceuticals Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Reig Jofre

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Reig Jofre

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Mupirocin Gel in Children With Impetigo

                            Details : Mupirocin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Impetigo.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            February 27, 2020

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Harvard Pilgrim Health Care

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Harvard Pilgrim Health Care

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Hospital Corporation of America | University of California, Irvine | University of Massachusetts, Amherst | Rush University | Centers for Disease Control and Prevention

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mupirocin-Iodophor ICU Decolonization Swap Out Trial

                            Details : Mupirocin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Staphylococcus aureus.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            May 04, 2017

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Hospital Corporation of America | University of California, Irvine | University of Massachusetts, Amherst | Rush University | Centers for Disease Control and Prevention

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lindenhofgruppe AG

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lindenhofgruppe AG

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Clinical Trials Unit Bern | Lindenhofstiftung | Labormedizinisches Zentrum Dr. Risch

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial

                            Details : Mupirocin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Musculoskeletal Diseases.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 25, 2015

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Clinical Trials Unit Bern | Lindenhofstiftung | Labormedizinisches Zentrum Dr. Risch

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Destiny Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Destiny Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal...

                            Details : Mupirocin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Staphylococcal Infections.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            November 06, 2014

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Horizon Health Network

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Horizon Health Network

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting

                            Details : Mupirocin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Surgical Wound Infection.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 25, 2013

                            Lead Product(s) : Mupirocin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth